Guangdong Biolight Meditech vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Guangdong Biolight Meditech Co Ltd (300246.CS)

Q3 202623 Jul – 24 Aug 2026

▲2▼2

Biolight's control-change deal collapsed, losses deepened, but new device approvals and BCI hype lifted shares

Control-change plan terminated, stock crashed The controlling shareholder's plan to sell control was called off, and when trading resumed the stock fell 20% in one day. Investors who had bought hoping for a buyout lost that hope, and the company remains without a new owner or fresh capital.
This is the single biggest new event of the period and directly explains the sharp price drop.
Interim loss widens, revenue and margins shrink The 2026 half-year report showed a net loss of 34.49 million yuan, swinging from profit to loss a year earlier. Revenue slipped 1.09%, gross margin fell to 22.86%, and debt rose, showing the core business is still struggling.
The weak financial results confirm the company's underlying problems and weigh on the stock.
New blood purification devices approved for sale Biolight received Class III medical device registration certificates for its Elix-Ω and Elix-90 blood purification devices, allowing them to be sold in China until 2031. This opens a new product line and potential future revenue.
This is a concrete positive regulatory step that could support future growth.
Brain-computer interface policy sparks 20% surge Zhejiang province issued measures to boost brain-computer interface technology, and Biolight's stock jumped 20% in afternoon trading as part of a sector rally. The move is sentiment-driven and may not reflect Biolight's own fundamentals.
This explains a sharp one-day price jump and shows how policy news can move the stock.

August 202623 Jul – 24 Aug 2026

▲2▼2

Biolight's control-change deal collapsed, losses deepened, but new device approvals and BCI hype lifted shares

Control-change plan terminated, stock crashed The controlling shareholder's plan to sell control was called off, and when trading resumed the stock fell 20% in one day. Investors who had bought hoping for a buyout lost that hope, and the company remains without a new owner or fresh capital.
This is the single biggest new event of the period and directly explains the sharp price drop.
Interim loss widens, revenue and margins shrink The 2026 half-year report showed a net loss of 34.49 million yuan, swinging from profit to loss a year earlier. Revenue slipped 1.09%, gross margin fell to 22.86%, and debt rose, showing the core business is still struggling.
The weak financial results confirm the company's underlying problems and weigh on the stock.
New blood purification devices approved for sale Biolight received Class III medical device registration certificates for its Elix-Ω and Elix-90 blood purification devices, allowing them to be sold in China until 2031. This opens a new product line and potential future revenue.
This is a concrete positive regulatory step that could support future growth.
Brain-computer interface policy sparks 20% surge Zhejiang province issued measures to boost brain-computer interface technology, and Biolight's stock jumped 20% in afternoon trading as part of a sector rally. The move is sentiment-driven and may not reflect Biolight's own fundamentals.
This explains a sharp one-day price jump and shows how policy news can move the stock.

Latest23 Jul – 24 Aug 2026

▲2▼2

Biolight's control-change deal collapsed, losses deepened, but new device approvals and BCI hype lifted shares

Control-change plan terminated, stock crashed The controlling shareholder's plan to sell control was called off, and when trading resumed the stock fell 20% in one day. Investors who had bought hoping for a buyout lost that hope, and the company remains without a new owner or fresh capital.
This is the single biggest new event of the period and directly explains the sharp price drop.
Interim loss widens, revenue and margins shrink The 2026 half-year report showed a net loss of 34.49 million yuan, swinging from profit to loss a year earlier. Revenue slipped 1.09%, gross margin fell to 22.86%, and debt rose, showing the core business is still struggling.
The weak financial results confirm the company's underlying problems and weigh on the stock.
New blood purification devices approved for sale Biolight received Class III medical device registration certificates for its Elix-Ω and Elix-90 blood purification devices, allowing them to be sold in China until 2031. This opens a new product line and potential future revenue.
This is a concrete positive regulatory step that could support future growth.
Brain-computer interface policy sparks 20% surge Zhejiang province issued measures to boost brain-computer interface technology, and Biolight's stock jumped 20% in afternoon trading as part of a sector rally. The move is sentiment-driven and may not reflect Biolight's own fundamentals.
This explains a sharp one-day price jump and shows how policy news can move the stock.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.